TORUTAMIG
UNII N89BPG3SVA
Substance Identification & Data
This profile provides standardized clinical and technical data for Torutamig, uniquely identified by the FDA Unique Ingredient Identifier (UNII) N89BPG3SVA.
Technical mappings include the Chemical Abstracts Service (CAS) Registry Number 3075939-10-2 and the RxNorm Concept ID (RxCUI) N/A. Explore the sections below for detailed nomenclature and a complete directory of NDC-listed products containing this ingredient.
N89BPG3SVA
3075939-10-2
N/A
Detailed Substance Profile
Preferred Name
TORUTAMIG
Official standardized name for this substance within the FDA UNII nomenclature system.
INN ID
13997
Sequential identifier assigned via the WHO International Nonproprietary Name program.
Substance Type
Torutamig
ISO 11238 classification category (e.g., Chemical, Polymer, Protein).
Synonyms and Nomenclature
This section provides a complete list of nomenclature and identifier mappings for Torutamig. Identifiers are organized into official regulatory terms, commercial trade names, and technical systematic synonyms used to ensure accurate identification across clinical pharmaceutical databases, regulatory filings, and electronic health records.
FDA Official Name
Torutamig
Common Names & Synonyms
H-gamma1 heavy chain anti-TNFRSF17 chimeric hole (H) (1-451) [VH (Lama glama IGHV3S6*01 (82.5%) -(IGHD) -IGHJ6*01 (100%)/Homo sapiens IGHV3-66 (81.8%) -(IGHD) -IGHJ4*01 (93.3%), CDR-IMGT [8.8.14] (26-33.51-58.97-110)) (1-121) -Homo sapiens IGHG1*01v, G1m17,1>G1m3,1 CH1 R120, CH3 D12, L14, 6-G1v14 CH2 A1.3, A1.2, 9-G1v21 CH2 Y15.1, T16, E18, 14-G1v75 CH3 C5, 14-G1v33 CH3 S22, A24, V86 (hole) (CH1 R120 (218) (122-219), hinge 1-15 (220-234), CH2 L1.3>A (238), L1.2>A (239), M15.1>Y (256), S16>T (258), T18>E(260)(235-344), CH3 Y5>C (353), D12 (360), L14 (362), T22>S (370), L24>A (372), Y86>V (411) (345-449), CHS (450-451)) (122-451)], (224-217')-disulfide with V-lambda-C-kappa light chain anti-TNFRSF17 Homo sapiens (1'-217') [V-LAMBDA (Homo sapiens IGLV1-36*01 (89.7%) -IGLJ3*02 (91.7%), CDR-IMGT [8.3.11] (26'-33'.51'-53'.90'-100')) (1'-110') -Homo sapiens IGKC*01 (100%) Km3 A45.1, V101 (C-KAPPA A45.1 (156'), V101 (194')) (111'- 217')]; V-kappa-C-gamma1 heavy chain anti-CD3E Homo sapiens knob (H'') (1''-438'') [V-KAPPA (Homo sapiens IGKV3-15*01 (93.7%) -IGKJ4*01 (81.8%), CDR-IMGT [6.3.9] (27''-32''.50''-52''.89''-97''), 12-KVv1 T125, V126, S127, S128 (E125>T (105''), I126>V (106''), K127>S (107''), InsS128 (108'')) (1''-108'') -Homo sapiens IGHG1*01v, G1m17,1>G1m3,1 CH1 R120, CH3 D12, L14, 6-G1v14 CH2 A1.3, A1.2, 9-G1v21 CH2 Y15.1, T16, E18, 14-G1v74 CH3 C10, 14-G1v32 CH3 W22 (knob) (CH1 R120 (205'') (109''-206''), hinge 1-15 (207''-221''), CH2 L1.3>A (225''), L1.2>A (226''), M15.1>Y (243''), S16>T (245''), T18>E (247'')(222''-331''), CH3 S10>C (345''), D12 (347''), L14 (349''), T22>W (357'') (332''-436''), CHS (437''-438'')) (109''-438'')], (211''-229''')-disulfide with VH-C-kappa light chain anti-CD3E Homo sapiens (1'''-229''') [VH (Homo sapiens IGHV3-9*01 (93.9%) -IGHGD -IGHJ6*01 (76.5%), CDR-IMGT [8.8.16] (26'''-33'''.51'''-58'''.97'''-112''')) (1'''-122''') -Homo sapiens IGKC*01 (100%) Km3 A45.1, V101 (C-KAPPA A45.1 (168'''), V101 (206''')) (123'''-229''')]; dimer (230-217'':233-220'':353-345'')-trisdisulfide, produced in Chinese hamster ovary (CHO) cells, glycoform alfa
Immunoglobulin G1, bispecific, [238-alanine,239-alanine,256-tyrosine,258-threonine,260-glutamic acid,353-cysteine,370-serine,372-alanine,411-valine], anti-(human tumor necrosis factor receptor superfamily protein TNFRSF17) (human-Lama glama monoclonal BCD-248 γ1-chain), disulfide with human monoclonal BCD-248 κ-chain, (230→217′),(233→220′),(353→345′)-tris(disulfide) with immunoglobulin anti-(human CD3 antigen) (human monoclonal BCD-248 light chain variable region) fusion protein with peptide linker (TVSS) fusion protein with immunoglobulin G1 [117′-alanine,118′-alanine,135′-tyrosine,137′-threonine,139′-glutamic acid,237′-cysteine,249′-tryptophan] (human γ1-chain constant region) disulfide with immunoglobulin (human monoclonal BCD-248 heavy chain variable region) fusion protein with peptide linker (EIK) fusion protein with human monoclonal BCD-248 κ-chain constant region
immunoglobulin (H-gamma1_V-lambda-C-kappa)_(V-kappa-C-gamma1_VH-C-kappa), anti-[Homo sapiens TNFRSF17 (tumor necrosis factor (TNF) receptor superfamily member 17, B cell maturation antigen, BCMA, TNFRSF13A, CD269)] and anti-[Homo sapiens CD3E (CD3 epsilon, Leu-4)], chimeric, Homo sapiens monoclonal antibody, bispecific, bivalent (torutamig)
torutamig [INN]
